Current regulations tend to focus on AI developers and purchasers, leaving end-users - the doctors, nurses, and clinicians ...

Insilico Medicine, whose Hong Kong IPO application lapsed in 2024, is still considering going public in the city, said ...

As health care costs continue to rise and the burden of chronic disease grows, data-driven insights will be essential in ...

When it comes to real-world evaluation, appropriate benchmarks need to be carefully selected to match the context of AI ...

Insilico Medicine Inc. is considering an initial public offering after securing funding at a valuation of more than $1 ...

Insilico Medicine（“Insilico”）是一家临床阶段生成人工智能（AI）驱动的生物技术公司，最近宣布其特发性肺纤维化（IPF）的突破性候选药物Rentosertib（以前称为ISM001-055）已被美国采用名称（USAN）委员会授予正式通用名称。Rentosertib是第一个使用生成式人工智能发现生物靶点和治疗化合物的研究药物。

Tempus AI, Inc. TEM recently announced the acquisition of Deep 6 AI, a leading artificial intelligence (AI) company ...

Alongside new steps in its therapeutic pipeline—and a new push into laboratory robotics—Insilico Medicine has raised $110 ...

据彭博报道，香港人工智能生物科技公司英矽智能 (Insilico Medicine Inc.) 完成新一轮融资後，考虑重启香港IPO计划，预料将以超过10亿美元的估值申请上市。

Ataraxis AI, the leading AI precision medicine company, today announced its $20.4 million Series A financing led by AIX ...

Insilico Medicine('Insilico'), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced today that it has successfully secured a $110 million Series E ...